Rinsho Shinkeigaku (Clinical Neurology)


Clinical features of anti-IgLON5 disease

Takayoshi Shimohata, M.D., Ph.D.1) and Akio Kimura, M.D., Ph.D.1)

1) Department of Neurology, Gifu University Graduate School of Medicine

Anti-IgLON5 diseases were first reported in 2014 as sleep disorders such as parasomnia and obstructive sleep apnea. The pathological findings were suggestive of tauopathies and eight clinical subtypes have been reported so far. Serum and cerebrospinal fluid anti-IgLON5 antibodies should be measured in patients with sleep-related disorders with parasomnia as well as in patients with movement disorders, motor neuron disease or dementia with characteristic parasominia. The prognosis is generally poor, but some patients have been reported to improve with immunotherapy. Early diagnosis and early immunotherapy may improve the prognosis.
Full Text of this Article in Japanese PDF (2089K)

(CLINICA NEUROL, 61: 825|832, 2021)
key words: anti-IgLON5 disease, parasomnia, movement disorders, tauopathy, immunotherapy

(Received: 19-Jul-21)